pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,863 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1864Endpoints1447Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls
therapy area
allOncology12886Rare Disease3335Immunology3022Cardiology2847Hematology2298Pulmonology2253Vaccines
  • nChroma Bio stops its only clinical study early, lays off 50%
    A couple of years ago, two Boston-area biotech CEOs decided to merge their startups, hoping to survive a down market for genetic medicine companies. Jeff Walsh, the CEO of that combined company, nC…
    Endpoints · 48m ago↗ source
  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    BioPharma Dive · 5h ago↗ source
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
← prev
page 2 of 115
next →
120
fda medwatch114
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1133
Endocrinology & Metabolism807
Pain791
Nephrology783
BioSpace · 6h ago
↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • Isomorphic Labs lands record $5 billion Series C, marking biggest private biotech raise ever
    Isomorphic Labs, a Google-backed biotech company, announced a $5 billion Series C financing round. The round, completed just six months after a $2.1 billion raise, is the largest private capital r…
    Endpoints · 1d agoDealPositive↗ source
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 1d agoDealPositive↗ source
  • Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approval
    Vertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
    BioSpace · 1d agoRegulatoryPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 1d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 1d agoApprovalPositive↗ source
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C
    Beren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
    Endpoints · 1d agoApprovalPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitability
    Genetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
    BioSpace · 1d agoEarningsPositive↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 1d agoRegulatoryNegative↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trial
    German biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disorders
    Marrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
    BioSpace · 1d agoDealPositive↗ source
  • Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competition
    Marrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
    Endpoints · 1d agoDealPositive↗ source
  • Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion sets
    Cardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…
    fda medwatch · 1d agoCRLNegative↗ source
  • Heidi Overton faces Senate committee vote on FDA commissioner nomination amid uncertainty
    The Trump administration’s nominee for FDA commissioner, Heidi Overton, is scheduled for a vote before the Senate health, education, labor and pensions committee. Lawmakers have not indicated a cl…
    Endpoints · 1d agoRegulatoryNeutral↗ source
  • Cognito Therapeutics readies FDA submission for Alzheimer's light-and-sound headset after trial miss
    Cognito Therapeutics is preparing an FDA submission for its Spectris device, a headset that delivers patterned light and sound therapy aimed at treating Alzheimer's disease. The technology builds o…
    Endpoints · 1d agoRegulatoryNeutral↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Novo revamps NovoCare DTC platform as Roche’s Gazyva receives renewed approval
    Novo announced a revamp of its direct-to-consumer service, NovoCare, describing it as a reimagined platform for patients. The update includes a refreshed user interface and expanded resources aime…
    Endpoints · 1d agoRegulatoryNeutral↗ source
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 1d agoPositive↗ source